Florian Denis News Today

While the world keeps getting better at churning semiconductors, we are still struggling to find new drugs to treat resistant diseases, and the process isn't getting cheaper. "Today, drug development still takes on average 10-15 years of R&D with a cost of production (around $2.5 billion) that has increased dramatically over the last decade despite improvements in technology: this is the concept of Eroom's law (Moore’s law spelled backwards)," deep tech VC Floria...

The biotech startup's $6.5 million seed round is led by VC firm NFX but it is perhaps equally noteworthy to see that Merck is also participating in the round.

While the world keeps getting better at churning semiconductors, we are still struggling to find new drugs to treat resistant diseases, and the process isn't getting cheaper. "Today, drug development still takes on average 10-15 years of R&D with a cost of production (around $2.5 billion) that has increased dramatically over the last decade despite improvements in technology: this is the concept of Eroom's law (Moore’s law spelled backwards)," deep tech VC Floria...

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners

Investegate announcements from Mablink Bioscience, Mablink Bioscience announces a 31 million Series A

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door